Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764187 | 0.99 | KDM4E (0.60) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL2762653 | 0.95 | KDM4E (0.62) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL14697091 | 0.90 | PTGS2 (0.60) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL2763195 | 0.89 | KDM4E (0.57) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL554495 | 0.86 | PTGS2 (0.61) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL13109053 | 0.85 | KDM4E (0.79) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL973615 | 0.85 | KDM4E (0.79) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL15941675 | 0.84 | ALDH1A1 (0.59) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL555682 | 0.83 | PTGS2 (0.65) | KDM4EKMT2AMEN1RECQLPTGS2 | |
| SCHEMBL3765406 | 0.83 | KDM4E (0.81) | KDM4EKMT2AMEN1RECQLPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2398761-A2 | CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS | Bezwada Biomedical, LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-1951653-B1 | SALICYLIC ACID DERIVATIVES | NICOX SA (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010096320-A2 | CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080293781-A1 | Salicylic Acid Derivatives | NICOX S.A. (FR) | 2008-11-27 | — | — | US | disclosed |
| US-20080293781-A1 | Salicylic Acid Derivatives | NICOX S.A. (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1951653-A1 | SALICYLIC ACID DERIVATIVES | NicOx S.A. (FR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007060112-A1 | SALICYLIC ACID DERIVATIVES | NICOX S.A. (FR) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060112-A1 | SALICYLIC ACID DERIVATIVES | NICOX S.A. (FR) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | KDM4E 960/4885KMT2A 4360/4885MEN1 1770/4885 |
| US-20080293781-A1 | Salicylic Acid Derivatives | PTGS2, PTGS1, PTGES2 | KDM4E 2665/4885KMT2A 2780/4885MEN1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.